Efficacy and Safety of Meloxicam (Mobicox®) in Mexican Population With Rheumatic Diseases

Osteoarthritis Clinical Trial

Official title:

Clinical Therapeutic Evaluation Program in Patients With Rheumatic Diseases

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02184039
• Other study ID #: 107.264
• Status: Completed
• Phase: N/A
• First received: July 3, 2014
• Last updated: July 8, 2014
• Start date: May 2003

Study information

• Verified date: July 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Mexico: Ministry of Health
• Study type: Observational

Clinical Trial Summary

Study to evaluate the efficacy and safety of meloxicam (Mobicox®) in Mexican population with rheumatic diseases.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12687
• Est. primary completion date: July 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

Exclusion Criteria:

• Hypersensitivity to meloxicam or to other NSAIDS

• History of asthma, angioedema or urticaria secondary to NSAIDS

• Pregnancy or lactation

• Recent or current history of peptic ulcer disease, severe renal failure, severe hepatic failure

• Age below of 12 years.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Osteoarthritis
• Rheumatic Diseases

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in intensity of the symptoms measured with a four-point scale		Baseline, 30 and 90 days	No
Secondary	Degree of satisfaction evaluated with a six point numerical rating scale		up to 90 days	No
Secondary	Number of patients with adverse events		up to 90 days	No

External Links

•   Link